Técnica de Aspiração Dupla Contínua com Sistema Zoom para AVC (ADAPT 2 0)
Avaliação Clínica da Técnica de Aspiração Dupla Contínua com o Sistema Zoom para AVC (ADAPT 2.0)
This study is designed to evaluate the effectiveness, safety and clinical performance of ADAPT 2.0, first-line aspiration neurothrombectomy with Zoom System with Continuous Dual Aspiration Technique (CDAT).
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Tipo de estudo
Tipo de estudo
Inscrição (Estimado)
Inscrição
Contactos e Locais
Contato de estudo
Contato de estudo
- Nome: Pojai Phattanagosai
- Número de telefone: 650-740-7703
- E-mail: pphattanagosai@Imperativecare.com
Estude backup de contato
- Nome: Emma Pham
- Número de telefone: 408-421-7684
- E-mail: epham@imperativecare.com
Locais de estudo
-
-
Alabama
-
Huntsville, Alabama, Estados Unidos, 35801
- Recrutamento
- Huntsville Hospital
-
Contato:
- Farrar Hickey
-
Investigador principal:
- R. Dana Tomalty, MD
-
-
California
-
Walnut Creek, California, Estados Unidos, 94598
- Recrutamento
- John Muir Health
-
Investigador principal:
- Benjamin Yim, MD
-
Contato:
- Melenie Aaron
-
-
Florida
-
Tampa, Florida, Estados Unidos, 33606
- Recrutamento
- University of South Florida
-
Investigador principal:
- Maxim Mokin, MD
-
Contato:
- Kilaun Robinson
-
-
Georgia
-
Marietta, Georgia, Estados Unidos, 30060
- Recrutamento
- Wellstar Kennestone Hospital
-
Contato:
- Autumn Lee
-
Investigador principal:
- Ahmad Khaldi, MD
-
-
Louisiana
-
Lafayette, Louisiana, Estados Unidos, 70503
- Recrutamento
- Ochsner Clinic Foundation (Lafayette)
-
Investigador principal:
- Shail Thanki, MD
-
New Orleans, Louisiana, Estados Unidos, 70121
- Recrutamento
- Ochsner Clinic Foundation
-
Investigador principal:
- James Milburn, MD
-
Contato:
- Jessica Henry
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21201
- Recrutamento
- University of Maryland
-
Investigador principal:
- Jacob Cherian, MD
-
Contato:
- Katie Henry
-
-
Minnesota
-
Minneapolis, Minnesota, Estados Unidos, 55407
- Recrutamento
- Allina Health
-
Contato:
- Emeryth Beloy
-
Investigador principal:
- Collin Torok, MD
-
-
New York
-
Albany, New York, Estados Unidos, 12208
- Recrutamento
- Albany Medical College
-
Investigador principal:
- Alexandra Paul, MD
-
Contato:
- Chelsey Large
-
Buffalo, New York, Estados Unidos, 14203
- Recrutamento
- University at Buffalo Neurosurgery
-
Investigador principal:
- Jason Davies, MD
-
Contato:
- Ellen Carl
-
New York, New York, Estados Unidos, 10065
- Recrutamento
- Weill Cornell Medicine
-
Contato:
- Hanah Hwang
-
Investigador principal:
- Amol Mehta, MD
-
New York, New York, Estados Unidos, 10029
- Recrutamento
- Icahn School of Medicine at Mount Sinai
-
Contato:
- Kevin Buttet
-
Investigador principal:
- Michael T Caton, MD
-
Syracuse, New York, Estados Unidos, 13210
- Recrutamento
- SUNY Upstate Medical Center
-
Contato:
- Saptarshi Prachi
-
Investigador principal:
- Haydn Hoffman, MD
-
The Bronx, New York, Estados Unidos, 10467
- Recrutamento
- Montefiore Medical Center
-
Contato:
- Genesis Liriano
-
Investigador principal:
- Amanda Baker, MD
-
-
Ohio
-
Cincinnati, Ohio, Estados Unidos, 45220
- Recrutamento
- TriHealth Good Samaritan Hospital
-
Investigador principal:
- Andrew Ringer, MD
-
Contato:
- Mehnaaz Ali
-
Columbus, Ohio, Estados Unidos, 43221
- Recrutamento
- The Ohio State University Wexner Medical Center
-
Investigador principal:
- Patrick Youssef, MD
-
Investigador principal:
- Shahid Nimjee, MD
-
Contato:
- Edward Belizaire
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Estados Unidos, 73104
- Recrutamento
- University of Oklahoma, Health Science Center
-
Investigador principal:
- Hakeem Shakir, MD
-
Contato:
- Sanaa Hameed
-
-
South Carolina
-
Greenville, South Carolina, Estados Unidos, 29605
- Recrutamento
- Prisma Health - Upstate
-
Contato:
- Shawn Manos
-
Investigador principal:
- Jan Vargas Machaj, MD
-
-
Tennessee
-
Knoxville, Tennessee, Estados Unidos, 37902
- Recrutamento
- Fort Sanders Regional Medical Center
-
Contato:
- Cameron Carter
-
Investigador principal:
- Robert Hixson, MD
-
Memphis, Tennessee, Estados Unidos, 38120
- Recrutamento
- Semmes Murphey Foundation
-
Investigador principal:
- Lucas Elijovich, MD
-
Contato:
- Wendell Barnett
-
-
Texas
-
Kingwood, Texas, Estados Unidos, 77339
- Recrutamento
- HCA Houston Healthcare Kingwood
-
Investigador principal:
- Mohamad Ezzeldin, MD
-
Contato:
- Swathi Potla
-
San Antonio, Texas, Estados Unidos, 78229
- Recrutamento
- Methodist Healthcare System of San Antonio
-
Contato:
- Samantha Franklin
-
Investigador principal:
- Lee Birnbaum, MD
-
San Antonio, Texas, Estados Unidos, 78229
- Recrutamento
- University of Texas Science Health Center at San Antonio
-
Investigador principal:
- Justin Mascitelli, MD
-
Contato:
- Athena Lazaris-Conner
-
-
Utah
-
Salt Lake City, Utah, Estados Unidos, 84112
- Recrutamento
- University of Utah
-
Contato:
- Andrew Grandemange
-
Investigador principal:
- Robert Rennert, MD
-
-
Virginia
-
Falls Church, Virginia, Estados Unidos, 22042
- Recrutamento
- Inova Fairfax Medical Campus
-
Contato:
- Lauren Monroe
-
Investigador principal:
- James McEachern, MD
-
-
Washington
-
Spokane, Washington, Estados Unidos, 99204
- Recrutamento
- Providence Sacred Heart Medical Center and Children's Hospital
-
Contato:
- Kyle Kramer
-
Investigador principal:
- Christopher Zylak, MD
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Adult subjects with acute ischemic stroke secondary to large vessel occlusion (LVO) meeting the study eligibility criteria and providing written informed consent.
Descrição
Inclusion Criteria:
- Subject is ≥ 18 years of age
- Subject or legally authorized representative has provided written informed consent prior to any study-specific procedures and no later than 72 hours after the index procedure
- Pre-stroke mRS 0-2
- Subject is undergoing or has undergone an aspiration thrombectomy using the Zoom System with Continuous Dual Aspiration Technique (CDAT) as the first line device within its intended use
Exclusion Criteria:
- Subjects with a life expectancy of less than 6 months
- Female subject who is known to be pregnant at time of admission
- Any intracranial hemorrhage in the qualifying head CT or MRI
- Presence of tandem internal carotid artery occlusion, multiple occlusion locations (e.g., cavernous ICA and M1, separate M2 occlusions, etc.), or occlusions in multiple territories (e.g., MCA and ACA, bilateral, etc.).
- In the opinion of the Investigator, the patient is not a suitable candidate for intervention with the Zoom System
- Subject is currently enrolled in or planned to be enrolled in any concurrent interventional study that may impact the safety or performance data collected in this study
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: COHORT
- Perspectivas de Tempo: PROSPECTIVE
Número de grupos/coortes
Coortes e Intervenções
Grupo / CoorteGrupo / Coorte |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
ADAPT 2.0: Zoom System with Continuous Dual Aspiration Technique (CDAT)
The Zoom System is intended to be used as the first-line device and utilized within the FDA-cleared indications for use, consistent with the approved labeling and intended anatomical targets. |
Aspiration neurothrombectomy using Zoom System with Continuous Dual Aspiration Technique (CDAT)
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Proportion of patients achieving modified Thrombolysis in Cerebral Infarction (mTICI) score of ≥2c at the end of procedure, as adjudicated by independent core-lab
Prazo: End of procedure
|
mTICI scale ranges from 0 to 3, with higher scores indicating better reperfusion. mTICI 0: No antegrade reperfusion; mTICI 1: Antegrade reperfusion past initial occlusion, limited distal filling; mTICI 2a: Antegrade reperfusion of less than half (<50%) of the previously occluded target artery's ischemic territory; mTICI 2b: Antegrade reperfusion of more than half (≥50%) of the previously occluded target artery's ischemic territory; mTICI 2c: Near-complete (90-99%) reperfusion, or filling of all distal branches with slower flow; mTICI 3: Complete antegrade reperfusion of all branches |
End of procedure
|
|
Rate of Embolization to New Territory (ENT) on final angiography at the end of the procedure by investigator assessment
Prazo: End of procedure
|
Embolization to New Territory (ENT), defined as the presence of new occlusions on final angiography that occur in vascular territories remote from those effected by index stroke, as assessed by the investigator |
End of procedure
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Time to achieve mTICI≥2c, defined as groin puncture to investigator assessment for mTICI≥2c
Prazo: Intraprocedural
|
The time from groin puncture to mTICI (modified treatment in cerebral infarction) score ≥ 2c using study device and technique. mTICI scale ranges from 0 to 3, with higher scores indicating better reperfusion. mTICI 0: No antegrade reperfusion; mTICI 1: Antegrade reperfusion past initial occlusion, limited distal filling; mTICI 2a: Antegrade reperfusion of less than half (<50%) of the previously occluded target artery's ischemic territory; mTICI 2b: Antegrade reperfusion of more than half (≥50%) of the previously occluded target artery's ischemic territory; mTICI 2c: Near-complete (90-99%) reperfusion, or filling of all distal branches with slower flow; mTICI 3: Complete antegrade reperfusion of all branches |
Intraprocedural
|
|
Proportion of cases with clot ingestion, as evidenced by clot captured within the Zoom POD
Prazo: Intraprocedural
|
Proportion of cases with clot ingestion, as evidenced by clot captured within at least one of the Zoom PODs |
Intraprocedural
|
|
Proportion of cases with clot captured within the Zoom POD connected to the outer aspiration catheter
Prazo: Intraprocedural
|
Proportion of cases with clot ingestion, as evidenced by clot captured within the outer Zoom PODs |
Intraprocedural
|
|
Rate of rescue therapy
Prazo: Intraprocedural
|
Proportion of cases with rescue therapy, defined as unplanned use of another manufacturer's thrombectomy device, angioplasty, or stenting within the target vessel territory to achieve mTICI≥2c. |
Intraprocedural
|
|
Rate of functional independence (mRS 0-2) at 90 days
Prazo: 90 days post-procedure
|
Proportion of patients achieving mRS (modified Rankin Scale) ≤2 at 90 days mRS range: 0 to 6; The mRS scale ranges from 0 (no symptoms) to 5 (severe disability), with an additional category of 6 for death; higher score means worse outcome |
90 days post-procedure
|
|
Proportion of patients achieving First Pass Effect (FPE) mTICI ≥2c as adjudicated by independent core-lab
Prazo: Intraprocedural
|
Proportion of cases achieving First Pass Effect (FPE), defined as mTICI ≥2c after the first pass with the study device and technique as adjudicated by independent core-lab mTICI scale ranges from 0 to 3, with higher scores indicating better reperfusion. mTICI 0: No antegrade reperfusion; mTICI 1: Antegrade reperfusion past initial occlusion, limited distal filling; mTICI 2a: Antegrade reperfusion of less than half (<50%) of the previously occluded target artery's ischemic territory; mTICI 2b: Antegrade reperfusion of more than half (≥50%) of the previously occluded target artery's ischemic territory; mTICI 2c: Near-complete (90-99%) reperfusion, or filling of all distal branches with slower flow; mTICI 3: Complete antegrade reperfusion of all branches |
Intraprocedural
|
|
Rate of symptomatic intracranial hemorrhage (sICH), as confirmed by imaging and independently adjudicated by medical monitor, at the 24-hour post-procedure
Prazo: 24-hour post-procedure
|
Independently adjudicated rate of symptomatic intracranial hemorrhage (sICH) defined as any apparently extravascular blood in the brain or within the cranium confirmed by imaging that is associated with clinical deterioration as defined by an increase of four or more points in the NIHSS at 24 hours compared to the baseline assessment, or that led to death, and was judged to be the predominant cause of a neurologic deterioration or death, per ECASS III criteria |
24-hour post-procedure
|
|
90-day all-cause mortality
Prazo: 90 days post-procedure
|
Rate of all-cause mortality through 90 days post-procedure |
90 days post-procedure
|
|
Rate of device-related Serious Adverse Events, independently adjudicated medical monitor
Prazo: Intraprocedural
|
Independently adjudicated rate of Serious Adverse Events related to study device |
Intraprocedural
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Investigador principal: David Fiorella, MD, Stony Brook University
- Investigador principal: Shahram Majidi, MD, Icahn School of Medicine at Mount Sinai
- Investigador principal: Justin Masciteli, MD, The University of Texas Health Science Center at San Antonio
- Investigador principal: Maxim Mokin, MD, University of South Florida
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Distúrbios Cerebrovasculares
- Doenças Cerebrais
- Doenças do Sistema Nervoso Central
- Doenças do Sistema Nervoso
- Doenças Vasculares
- Doenças cardiovasculares
- AVC Isquêmico
- Derrame
- Procedimentos cirúrgicos, operatórios
- Procedimentos cirúrgicos vasculares
- Procedimentos cirúrgicos cardiovasculares
- Trombectomia
Outros números de identificação do estudo
Outros números de identificação do estudo
- ICI-2025-003
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .